# EDGAR Filing Document

**Accession Number:** 0000856984
**File Stem:** 0001641172-25-026187
**Filing Date:** 2025-9
**Character Count:** 13111
**Document Hash:** 3ce3628d8b6637a0b8e33ff9caa6a1e6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-026187.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0001641172-25-026187

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250902

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250902

**DATE AS OF CHANGE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QHSLab, Inc.
- **CENTRAL INDEX KEY:** 0000856984
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112655906
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19041
- **FILM NUMBER:** 251284272

**BUSINESS ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407
- **BUSINESS PHONE:** (929) 379-6503

**MAIL ADDRESS:**
- **STREET 1:** 901 NORTHPOINT PARKWAY
- **STREET 2:** SUITE 302
- **CITY:** WEST PALM BEACH
- **STATE:** FL
- **ZIP:** 33407

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITIES CORP.
- **DATE OF NAME CHANGE:** 20151119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** USA EQUITY CORP.
- **DATE OF NAME CHANGE:** 20151116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMERICAN BIOGENETIC SCIENCES INC
- **DATE OF NAME CHANGE:** 19940426

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (date of earliest event reported): September 2, 2025

**<u>QHSLab, Inc.</u>**

(Exact Name of Registrant as Specified in its Charter)

0-19041

(Commission File No.)

---

| | |
|:---|:---|
| Nevada | 30-1104301 |
| (State<br> of Incorporation) | (I.R.S. Employer<br> Identification No.) |
| 901 Northpoint Parkway Suite 302 West Palm Beach<br> FL 33407 | 33407 |
| (Address of Principal Executive Offices) | (ZIP Code) |

---

Registrant's telephone number, including area code: (929) 379-6503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

**Securities registered pursuant to Section 12(g) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.0001 par value** | **USAQ** | **N/A** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On September 2, 2025, QHSLab, Inc. (the "Company") issued a press release titled *"QHSLab (OTCQB: USAQ) Rolls Out Breakthrough Pediatric Screening Tool Linking Allergies and Mental Health."* A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (<u>https://twitter.com/qhslabinc</u>), LinkedIn account (<u>https://www.linkedin.com/company/65407282/</u>), Facebook account (<u>https://www.facebook.com/QHSLabs</u>) and Instagram account (<u>https://www.instagram.com/qhslabs/</u>) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

**Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated September 2, 2025 – *QHSLab (OTCQB: USAQ) Rolls Out Breakthrough Pediatric Screening Tool Linking Allergies and Mental Health*](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Date: September 2, 2025 | Date: September 2, 2025 |
| QHSLab, Inc. | QHSLab, Inc. |
|  | */s/ Troy Grogan* |
| Name: | Troy Grogan |
| Title: | CEO and Chairman |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

***QHSLab (OTCQB: USAQ) Rolls Out Breakthrough Pediatric Screening Tool Linking Allergies and Mental Health***

 

*Back-to-School Season Just Got Smarter*

 

*The Pediatric Health Assessment empowers parents and providers to uncover hidden health or behavioral issues that may affect academic and social success.*

 

*QHSLab's platform delivers critical insights at the perfect time for pediatricians to support whole-child wellness as families prepare for the new academic year.*

**West Palm Beach, FL, September 2, 2025 (GLOBE NEWSWIRE) — QHSLab Inc. (the "Company") (OTCQB: USAQ),** a leading provider in digital medicine solutions for primary care and specialty practices, today announced the recent launch of its new **Pediatric Health Assessment** with a prominent, multi-location pediatric group in Texas. The assessment is now live across the group's practices, aligning with the annual surge in back-to-school visits and well-child checkups.

The Pediatric Health Assessment is a **first-of-its-kind digital screening tool** that integrates evidence-based behavioral health screeners (including the PSC-17 and SDQ Prosocial scale), asthma/allergy control metrics (CARAT), over-the-counter allergy medication use, and help-seeking behaviors into a single, streamlined digital experience.

***"This tool goes far beyond traditional checklists,"*** said **Troy Grogan**, President and CEO of QHSLab. *"We're giving pediatricians real-time insight into how allergy symptoms, behavioral and developmental issues, as well as sleep problems overlap. This is especially powerful as kids return to classrooms — we're helping providers and parents catch things early before they escalate. This timely launch represents a significant commercial milestone for QHSLab"*

The tool's unique value lies in its **interconnected clinical data framework** — screening children for internalizing and externalizing symptoms, attention difficulties, social skill strengths, suicide or self-harm risk, and physical health drivers like poorly managed allergic rhinitis or asthma. This holistic approach enables providers to deliver precision care, providing QHSLab a differentiated position in the pediatric digital health market.

***"Pediatricians are often the first to see signs of anxiety, depression, ADHD, or sleep disturbances, but they rarely have time to assess all these factors in a single visit,"*** said **Dr. Juan Oms**, Psychiatrist and Medical Adviser to QHSLab. *"This tool brings together behavioral and physical health in a meaningful way, improving early detection for these often complex health issues, while respecting provider time and practice workflow."*

QHSLab has received IRB exemption to carry out observational research to evaluate the tool's population health impact. The study will investigate how the management of allergy symptoms—particularly those linked to poor sleep and medication misuse—relates to behavioral screening results. This study is part of QHSLab's broader data strategy to validate correlations between immune health and psychosocial risk factors, reinforcing the clinical and economic value of comprehensive screening tools that support early intervention.

***"The long-term value of this dataset should excite investors,"*** said **Dr. Marcos Sánchez-González, MD, PhD**, Vice President of Medical and Scientific Affairs. *"This opens the door to real-world evidence showing the interaction between immune health and mental health in children — data that could drive collaborations with pharma, payers, or public health systems focused on integrated care."*

For QHSLab (USAQ), the pediatric product line expands the company's recurring revenue model in a high-demand, reimbursement-friendly market. With the rising public health urgency around youth mental health, the product is well-positioned for broader adoption, strategic partnerships, and future licensing opportunities

Pediatrics practices interested in learning more can visit <u>https://www.qhslab.com/learning-lab/blog/smarter-pediatric-screening-tools-introducing-qhslabs-digital-health-assessment-for-children</u> or contact QHSLab directly at <u>hello@qhslab.com</u>.

**About QHSLab**

QHSLab, Inc. (OTCQB: USAQ) is a digital health technology leader providing preventive screening, assessment, and workflow solutions for primary care. Its tools help practices identify, document, and manage underdiagnosed chronic and behavioral conditions efficiently and profitably.

**Forward-Looking Statements**

Certain matters discussed in this press release are 'forward-looking statements' intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as 'may,' 'could,' 'believes,' 'estimates,' 'targets,' 'expects,' or 'intends,' and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

**Investor Relations Contact:**

Olivia Giamanco

QHSLab, Inc.

(929) 379-6503

<u>ir@usaqcorp.com</u>

<u>https://twitter.com/QHSLabInc</u>